- Title
- Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment
- Creator
- Shaw, Julia C.; Dyson, Rebecca M.; Palliser, Hannah K.; Sixtus, Ryan P.; Barnes, Heather; Pavy, Carlton L.; Crombie, Gabrielle K.; Berry, Mary J.; Hirst, Jonathan J.
- Relation
- NHMRC.APP1003517 http://purl.org/au-research/grants/nhmrc/1003517
- Relation
- Frontiers in Physiology Vol. 13, Issue 19 April 2022, no. 871265
- Publisher Link
- http://dx.doi.org/10.3389/fphys.2022.871265
- Publisher
- Frontiers Research Foundation
- Resource Type
- journal article
- Date
- 2022
- Description
- Background: Preterm birth can lead to brain injury and currently there are no targeted therapies to promote postnatal brain development and protect these vulnerable neonates. We have previously shown that the neurosteroid-analogue ganaxolone promotes white matter development and improves behavioural outcomes in male juvenile guinea pigs born preterm. Adverse side effects in this previous study necessitated this current follow-up dosing study, where a focus was placed upon physical wellbeing during the treatment administration and markers of neurodevelopment at the completion of the treatment period. Methods: Time-mated guinea pigs delivered preterm (d62) by induction of labour or spontaneously at term (d69). Preterm pups were randomized to receive no treatment (Prem-CON) or ganaxolone at one of three doses [0.5 mg/kg ganaxolone (low dose; LOW-GNX), 1.0 mg/kg ganaxolone (mid dose; MID-GNX), or 2.5 mg/kg ganaxolone (high dose; HIGH-GNX) in vehicle (45% β-cyclodextrin)] daily until term equivalence age. Physical parameters including weight gain, ponderal index, supplemental feeding, and wellbeing (a score based on respiration, activity, and posture) were recorded throughout the preterm period. At term equivalence, brain tissue was collected, and analysis of hippocampal neurodevelopment was undertaken by immunohistochemistry and RT-PCR. Results: Low and mid dose ganaxolone had some impacts on early weight gain, supplemental feeding, and wellbeing, whereas high dose ganaxolone significantly affected all physical parameters for multiple days during the postnatal period when compared to the preterm control neonates. Deficits in the preterm hippocampus were identified using neurodevelopmental markers including mRNA expression of oligodendrocyte lineage cells (CSPG4, MBP), neuronal growth (INA, VEGFA), and the GABAergic/glutamatergic system (SLC32A1, SLC1A2, GRIN1, GRIN2C, DLG4). These deficits were not affected by ganaxolone at the doses used at the equivalent of normal term. Conclusion: This is the first study to investigate the effects of a range of doses of ganaxolone to improve preterm brain development. We found that of the three doses, only the highest dose of ganaxolone (2.5 mg/kg) impaired key indicators of physical health and wellbeing over extended periods of time. Whilst it may be too early to see improvements in markers of neurodevelopment, further long-term study utilising the lower doses are warranted to assess functional outcomes at ages when preterm birth associated behavioural disorders are observed.
- Subject
- neurosteroids; preterm neonatal brain; oligodendrocyte; GABA; glutamate; neuron; SDG 3; SDG 17; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1482539
- Identifier
- uon:50958
- Identifier
- ISSN:1664-042X
- Rights
- © 2022 Shaw, Dyson, Palliser, Sixtus, Barnes, Pavy, Crombie, Berry and Hirst. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY), (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Language
- eng
- Full Text
- Reviewed
- Hits: 1828
- Visitors: 1842
- Downloads: 23
Collections
Goal 3: Good Health and Well-Being
Goal 17: Partnerships for the Goals
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 4 MB | Adobe Acrobat PDF | View Details Download |